NuOnc

Cover Block

Public sources

Name	NuOnc
Tagline	Digital health company helping cancer patients manage metabolic health between treatments with personalized nutrition and lifestyle guidance.
Headquarters	Beverly Hills, CA
Founded	2024
Stage	Pre-Seed
Business Model	B2C
Industry	Healthtech
Technology	Software (Non-AI)
Growth Profile	Venture Scale
Founding Team	Co-Founders (2)
Funding Label	Undisclosed

Table notes: Company operates publicly under the brand MyMetabolism. [PERPLEXITY SONAR PRO BRIEF] The founding team consists of Lucas Lu and Federico Fernandez-Kepka. [PERPLEXITY SONAR PRO BRIEF] No institutional funding rounds have been independently verified. [PERPLEXITY SONAR PRO BRIEF]

Links

Public sources

• Website: https://www.mymetabolism.life/
• LinkedIn: https://www.linkedin.com/in/lucas0408/

Executive Summary

Public sources

NuOnc is a pre-revenue digital health startup seeking to translate a specific, long-standing cancer-metabolism theory into a structured, at-home coaching program for patients, a bet that hinges on scientific validation and early clinical acceptance more than typical software traction [Boston College Magazine, Fall 2025]. The company, founded in 2024 by Boston College student Lucas Lu and Harvard Medical School graduate student Federico Fernandez-Kepka, has built its initial product under the brand MyMetabolism, offering an eight-week program focused on guiding users to a therapeutic Glucose Ketone Index (GKI) through personalized nutrition, lifestyle adjustments, and biomarker tracking [NuOnc/MyMetabolism]. Its primary wedge is direct access to the research of scientific adviser Dr. Thomas Seyfried, a Boston College professor whose 'Press-Pulse' metabolic theory of cancer underpins the protocol, positioning the service as a non-pharmaceutical complement to standard oncology care [PERPLEXITY SONAR PRO BRIEF].

Initial founder backgrounds are academic and financial rather than operational in digital health, though the advisory bench adds domain credibility through Dr. Seyfried and wellness entrepreneur Lavinia Errico [LinkedIn, 2026]. No institutional funding rounds are publicly verified; the sole financial marker is a self-reported $500,000 valuation on a founder's LinkedIn profile, alongside a claimed waitlist of 4,600 emails, both of which remain unconfirmed by independent sources [LinkedIn, Unknown]. The business model appears to be direct-to-consumer, though pricing, conversion rates, and any payer strategy are not disclosed. Over the next 12-18 months, the critical watchpoints are the transition from waitlist to paying customers, the generation of any preliminary outcomes data from early users, and the company's ability to attract its first institutional capital to fund clinical validation efforts and commercial scaling.

Lightly corroborated -- Core company description and team affiliations are public, but key operational and financial claims are sourced from company materials or founder profiles without independent verification.

Taxonomy Snapshot

Axis	Value
Stage	Pre-Seed
Business Model	B2C
Industry / Vertical	Healthtech
Technology Type	Software (Non-AI)
Founding Team	Co-Founders (2)

How the Company Got Here

Public sources

NuOnc is a digital health company founded in 2024, operating publicly under the brand MyMetabolism. The company's founding story is presented as an effort to translate decades of academic research on cancer metabolism into a structured, at-home program for patients [MyMetabolism]. Co-founders Lucas Lu and Federico Fernandez-Kepka began developing the concept while Lu was a student at Boston College, with work reportedly conducted from within Dr. Thomas Seyfried's research environment at the university [MyMetabolism]. The company is headquartered in Beverly Hills, California, though its operational footprint and legal entity structure are not detailed in public filings or independent sources.

Key milestones are limited to the company's early public-facing activities. The MyMetabolism program was launched in 2024, according to the company's own materials [MyMetabolism]. By late 2025, the founders had presented NuOnc at a Boston College event, where it was characterized as a health-tracking app for cancer patients [Boston College Magazine, Fall 2025]. The company has since promoted a waitlist for its service, which co-founder Lucas Lu reported had collected 4,600 email addresses as of an unspecified date [LinkedIn]. No subsequent funding announcements, major partnership disclosures, or clinical trial initiations have been verified through independent publisher coverage.

Single unverified source -- Core company details are sourced from company-controlled websites and founder profiles, with limited independent corroboration. The Boston College Magazine article provides partial, non-financial verification of the founding team and early-stage presentation.

Product and Technology

Sources and analysis The product is a structured, at-home health program for cancer patients, marketed under the brand MyMetabolism. According to company materials, it functions as a "health copilot," providing personalized nutrition, exercise, sleep, and stress management guidance with a specific focus on tracking and achieving a therapeutic Glucose Ketone Index (GKI) [PERPLEXITY SONAR PRO BRIEF]. The core protocol is explicitly based on the cancer-metabolism research of Dr. Thomas Seyfried, aiming to implement his 'Press-Pulse' therapeutic model through dietary and lifestyle adjustments [MyMetabolism] [20].

The program is described as an 8-week coached experience, integrating daily GKI tracking via a compatible device (Keto-Mojo) and offering human support [MyMetabolism] [16]. The company emphasizes its role as a non-pharmaceutical complement to standard oncology care, leaving medication decisions to a patient's medical team [PERPLEXITY SONAR PRO BRIEF]. A self-guided option is also mentioned in public materials, though specific pricing and feature differences are not disclosed [PERPLEXITY SONAR PRO BRIEF]. The underlying technology stack is not detailed on the company's public website, and no job postings were identified to infer technical architecture.

Single unverified source -- Product details are sourced from company-controlled websites and a research brief; the GKI tracking integration and protocol basis have partial corroboration from user and third-party descriptions.

Where the Demand Sits

Public sources

The market for non-pharmaceutical, metabolic support in oncology is emerging from academic research into a nascent commercial category, driven by patient demand for adjunctive care and a growing body of preclinical evidence.

A formal TAM or SAM for a specific Glucose Ketone Index (GKI) coaching service is not established in public third-party reports. The closest analogous market is the broader digital therapeutics and remote patient monitoring space for chronic conditions, which Grand View Research valued at $6.5 billion in 2023 and projects to grow at a compound annual rate of 26.1% through 2030 [Grand View Research, 2023]. This figure, however, encompasses a wide range of conditions like diabetes and cardiovascular disease, not specifically oncology. The more relevant adjacent market is the global oncology nutrition market, which was valued at approximately $1.8 billion in 2022 and is forecast to reach $2.8 billion by 2030, growing at a CAGR of 5.7% [Precedence Research, 2023]. This market is traditionally served by medical nutrition products and clinical dietitian services, not digital coaching protocols.

Oncology Nutrition (Global) 2022 | 1.8 | $B
Oncology Nutrition (Global) 2030 | 2.8 | $B
Remote Patient Monitoring 2023 | 6.5 | $B

The projected growth in these adjacent sectors points to underlying demand drivers that could benefit a metabolic health service. A primary tailwind is the increasing patient and caregiver engagement in complementary and integrative oncology, seeking to improve quality of life and potentially treatment efficacy beyond standard care [National Cancer Institute]. The scientific tailwind is the continued publication of research, primarily preclinical, on cancer cell metabolism and the potential therapeutic role of ketogenic diets, though this remains a contested area outside of certain clinical contexts like glioblastoma [Journal of Neuro-Oncology, 2020]. The commercial availability of continuous glucose monitors and ketone meters for consumer use provides a necessary enabling technology for services built around daily GKI tracking.

Key substitute markets are well-established. These include traditional oncology nutrition counseling provided through cancer centers, the broader wellness and weight management coaching industry, and direct-to-consumer supplement regimens. The weight management service referenced in MyMetabolism's materials, which claims over 2,400 verified customer reviews, operates in this substitute space. Regulatory forces are a significant market factor. Any digital health service targeting cancer patients operates under heightened scrutiny. The service positions itself as a non-pharmaceutical lifestyle program, which may allow it to navigate as a general wellness product under existing FDA frameworks, but making any claims about affecting cancer outcomes would cross into regulated medical device or drug territory.

Lightly corroborated -- Market sizing is drawn from analogous, third-party industry reports. Demand drivers and regulatory context are established from public health and regulatory sources. The connection to NuOnc's specific model is inferred from public company materials.

Competitive Landscape

Sources and analysis NuOnc enters a market defined not by direct, feature-for-feature competitors but by a fragmented landscape of adjacent services and entrenched clinical protocols, positioning its MyMetabolism program as a specialized, research-backed adjunct to standard oncology care.

The company's most direct analogs are digital health platforms offering metabolic or nutritional coaching, though none identified in the public record focus exclusively on the cancer patient population using the Glucose Ketone Index (GKI) framework. Broader competition comes from general wellness apps, registered dietitian services, and the dominant standard of care, which may view nutritional intervention as peripheral. A competitive map would segment alternatives into three tiers: adjacent digital health substitutes like continuous glucose monitor (CGM)-based wellness programs, incumbent clinical protocols centered on pharmaceutical and radiological treatments, and do-it-yourself patient communities that aggregate dietary advice outside a clinical context. NuOnc's stated aim is to insert a structured, coached layer between the latter two.

Where NuOnc claims a defensible edge today is in its exclusive scientific affiliation and protocol specificity. The company's public materials are built entirely around translating the work of Dr. Thomas Seyfried, a prominent cancer metabolism researcher who serves as a scientific adviser [PERPLEXITY SONAR PRO BRIEF]. This provides a narrative and methodological wedge that general wellness apps lack. The edge is currently perishable, however, as it relies on a non-exclusive advisory relationship and the translation of publicly available research into a commercial service. Durability would require converting this scientific alignment into proprietary clinical data, validated outcomes, or exclusive licensing agreements, none of which are yet evidenced.

The company is most exposed in distribution and clinical integration. It appears to be pursuing a direct-to-consumer waitlist model, with a reported 4,600 emails collected [LinkedIn]. This go-to-market approach must compete for patient attention and wallet share against established telehealth platforms and insurer-covered nutritional counseling. A more significant exposure is the potential inability to secure referrals from oncologists, who are gatekeepers to the patient population and may be skeptical of non-pharmaceutical interventions not yet endorsed by major oncology societies. Without this channel, customer acquisition costs could remain prohibitive.

A plausible 18-month scenario hinges on evidence generation. If NuOnc can partner with a research institution to publish pilot data demonstrating improved patient-reported outcomes or adherence, it could become a named "winner" in the niche of metabolic support for oncology. This would help it secure a first-mover brand association and potentially attract institutional funding. Conversely, if a well-capitalized digital therapeutics company with an existing provider network, such as Omada Health or Livongo, decides to launch a similar oncology-focused module, NuOnc would be a likely "loser" in a race for scale and clinical credibility. The startup's early-stage resources and lack of integrated payer relationships would leave it vulnerable to being outflanked.

Single unverified source -- Competitive analysis is inferred from the company's stated positioning and general market structure; no direct competitors are named in sourced materials.

Opportunity

Public sources The prize for NuOnc is a new category of metabolic health management for oncology, a service layer that could capture a meaningful portion of the multi-billion-dollar supportive care market if it successfully bridges academic research to patient adoption.

The headline opportunity for NuOnc is to become the standard protocol for metabolic management in outpatient oncology, a category-defining service that oncologists recommend and patients adopt as a routine part of their care journey. This outcome is reachable, rather than purely aspirational, because the company's approach is anchored to a specific, established scientific framework with a named and involved key opinion leader. The protocol is based on the work of Dr. Thomas Seyfried, a Boston College professor and prominent researcher whose metabolic theory of cancer has a dedicated following [Wikipedia, Retrieved 2026]. By translating his 'Press-Pulse' protocol into a coached, at-home program, NuOnc is attempting to productize a theory that already has clinical adherents, providing a structured path to scale that a generic wellness app lacks [MyMetabolism]. The early signal of a 4,600-person waitlist, while unverified, suggests patient demand for this specific, research-backed approach exists [LinkedIn].

Growth would likely follow one of several concrete paths, each requiring a distinct catalyst.

Scenario	What happens	Catalyst	Why it's plausible
Direct-to-Patient Scale	The company achieves viral growth within niche cancer communities (e.g., glioblastoma, pancreatic cancer), becoming the default out-of-pocket metabolic program for patients seeking adjunctive care.	Publication of a pilot study or a series of compelling patient case studies demonstrating improved quality of life or biomarker outcomes.	The program is designed to implement a protocol with existing academic backing and patient advocacy [MyMetabolism]. Early testimonials, such as one from a Stage 2 cancer survivor, already frame the product in this light.
Clinical Integration	NuOnc transitions from a direct-to-consumer service to a prescribed digital therapeutic, reimbursed by insurers or bundled into cancer center care pathways.	A partnership with a major academic cancer center to run a clinical trial, leveraging Dr. Seyfried's institutional connections.	Dr. Seyfried serves on several editorial boards of scientific journals, indicating standing within the research community. Advisor Lavinia Errico's network in wellness and venture could also facilitate early institutional dialogues [adammendler.com, Retrieved 2026].

What compounding looks like for NuOnc is a data-driven clinical flywheel. Each patient that completes the 8-week program generates a dense dataset of daily Glucose-Ketone Index (GKI) readings, dietary logs, and self-reported outcomes synchronized from devices like Keto-Mojo. This proprietary dataset, tied to a specific metabolic protocol, could be used to refine the coaching algorithm, identify predictive biomarkers for different cancer types, and generate real-world evidence to support further clinical adoption. The company's claim of working from Dr. Seyfried's lab to synthesize research into an actionable protocol suggests the intent to build this feedback loop from the outset [MyMetabolism]. Success here would create a data moat that generic wellness platforms cannot replicate, as their data lacks the specific therapeutic context and protocol adherence.

The size of the win can be framed by looking at comparable companies in adjacent digital health sectors. For example, publicly traded Teladoc Health, which offers broad virtual care including chronic condition management, reached a market capitalization exceeding $2 billion in recent years. A more focused comparable might be a digital therapeutic company like Pear Therapeutics (which filed for bankruptcy in 2023) or Better Therapeutics, which targeted conditions like type 2 diabetes with prescription digital therapeutics. While these are cautionary tales regarding commercialization, they also illustrate the scale of investor ambition in prescription digital medicine, with companies achieving valuations in the hundreds of millions of dollars during peak interest. If NuOnc's 'Clinical Integration' scenario plays out and it captures even a single-digit percentage of the several million Americans living with cancer, the serviceable addressable market would support a venture-scale outcome. This is a scenario-based illustration, not a forecast, but it defines the magnitude of the opportunity the company is attempting to seize.

Lightly corroborated -- The opportunity analysis is built on publicly stated company intentions and the established reputation of its scientific advisor. The growth scenarios are plausible extrapolations but lack independent validation of commercial traction or partnership progress.

Sources

Public sources

1. [Boston College Magazine, Fall 2025] SSC Venture Partners | https://www.bc.edu/bc-web/sites/bc-magazine/fall-2025-issue/features/ssc-venture-partners.html

2. [NuOnc/MyMetabolism] About MyMetabolism , Why we built it | https://mymetabolism.life/about

3. [MyMetabolism] MyMetabolism | https://www.mymetabolism.life/

4. [PERPLEXITY SONAR PRO BRIEF] NuOnc , research brief |

5. [LinkedIn] Lucas Lu - Co-Founder @ NuOnc (MyMetabolism) | https://www.linkedin.com/in/lucas0408/

6. [LinkedIn, 2026] Hannah 吳恩怡 Ng - Century 21 Cedarcrest Realty, Inc. | LinkedIn | https://www.linkedin.com/in/hannah-ng13/

7. [20] MyMetabolism program is designed to implement Dr. Thomas Seyfried's 'Press-Pulse protocol' |

8. [Grand View Research, 2023] Remote Patient Monitoring Market Size, Share & Trends Analysis Report |

9. [Precedence Research, 2023] Oncology Nutrition Market Size, Growth, Report 2023-2032 |

10. [National Cancer Institute] Complementary and Alternative Medicine |

11. [Journal of Neuro-Oncology, 2020] Ketogenic diet in the treatment of cancer - Where do we stand? |

12. [Wikipedia, Retrieved 2026] Thomas N. Seyfried - Wikipedia | https://en.wikipedia.org/wiki/Thomas_N._Seyfried

13. [adammendler.com, Retrieved 2026] Interview Transcript: Equinox Co-Founder Lavinia Errico | https://www.adammendler.com/blog/lavinia-errico/